Characterization of Patients Following Acute Venous Thromboembolism (VTE) and Safety and Effectiveness of Dabigatran Etexilate (DE) in the Treatment and Secondary Prevention of Acute Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) in Comparison to Vitamin K Antagonist (VKA) in Routine Clinical Practice - RE-COVERY DVT/PE

Trial Profile

Characterization of Patients Following Acute Venous Thromboembolism (VTE) and Safety and Effectiveness of Dabigatran Etexilate (DE) in the Treatment and Secondary Prevention of Acute Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) in Comparison to Vitamin K Antagonist (VKA) in Routine Clinical Practice - RE-COVERY DVT/PE

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 14 Jul 2017

At a glance

  • Drugs Dabigatran etexilate (Primary) ; Vitamin K antagonists
  • Indications Deep vein thrombosis; Pulmonary embolism
  • Focus Therapeutic Use
  • Acronyms RE-COVERY DVT/PE
  • Sponsors Boehringer Ingelheim
  • Most Recent Events

    • 17 Nov 2016 Trial design presented in the Thrombosis and Haemostasis.
    • 22 Feb 2016 Planned End Date changed from 1 Nov 2018 to 1 Dec 2018 according to ClinicalTrials.gov record.
    • 22 Feb 2016 Planned primary completion date changed from 1 Nov 2018 to 1 Dec 2018 according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top